title: [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
abstract: BACKGROUND
  We evaluated the efficacy and safety of chemotherapy with S-1/CDDP for advanced and recurrent gastric cancer at Fuchu Hospital.
  
  
  METHODS
  The participants were 24 patients treated at our hospital. S-1 was given orally at 80 mg/m/2 for days 1-21, and 60 mg/m2 of CDDP was administered on day 8, followed by a 2-week rest period, within a 5-week course.
  
  
  RESULTS
  Results were rated as a partial response in 12 cases and a stable response in 4 cases. The response rate was 50% (12/24), and median survival time was 273 days. The total incidence of grade 3 or greater adverse reactions including leucopenia, neutropenia, anemia, general fatigue, and eruption, was 25% (6/24).
  
  
  CONCLUSIONS
  The combination of S-1/CDDP therapy appears to be highly efficacious and safe and showed promise as a useful treatment strategy, even in an outpatient clinic.
authors.affiliation: Department of Surgery, Fuchu Hospital.
authors.forename: Yasutake
authors.initials: Y
authors.lastname: Uchima
authors.forename: Kinshi
authors.initials: K
authors.lastname: Kosaka
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Okita
authors.forename: Jin Kyu
authors.initials: JK
authors.lastname: Sim
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Hirata
authors.forename: Woo Ho
authors.initials: WH
authors.lastname: Lee
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Lee
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nishii
authors.forename: Seika
authors.initials: S
authors.lastname: Tei
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takeuchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin